Hansa Biopharma (Sweden) Performance
| HNSA Stock | SEK 31.00 0.50 1.59% |
The company retains a Market Volatility (i.e., Beta) of 0.14, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Hansa Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Hansa Biopharma is expected to be smaller as well. At this point, Hansa Biopharma AB has a negative expected return of -0.73%. Please make sure to check out Hansa Biopharma's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Hansa Biopharma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Hansa Biopharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 651.3 M | |
| Total Cashflows From Investing Activities | 229.5 M |
Hansa |
Hansa Biopharma Relative Risk vs. Return Landscape
If you would invest 5,195 in Hansa Biopharma AB on August 29, 2024 and sell it today you would lose (2,095) from holding Hansa Biopharma AB or give up 40.33% of portfolio value over 90 days. Hansa Biopharma AB is generating negative expected returns and assumes 3.4282% volatility on return distribution over the 90 days horizon. Simply put, 30% of stocks are less volatile than Hansa, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Hansa Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hansa Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hansa Biopharma AB, and traders can use it to determine the average amount a Hansa Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2143
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HNSA |
Estimated Market Risk
| 3.43 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.73 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hansa Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hansa Biopharma by adding Hansa Biopharma to a well-diversified portfolio.
Hansa Biopharma Fundamentals Growth
Hansa Stock prices reflect investors' perceptions of the future prospects and financial health of Hansa Biopharma, and Hansa Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hansa Stock performance.
| Return On Equity | -0.89 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (3.80) % | |||
| Current Valuation | 2.17 B | |||
| Shares Outstanding | 52.44 M | |||
| Price To Book | 7.52 X | |||
| Price To Sales | 17.67 X | |||
| Revenue | 154.53 M | |||
| EBITDA | (585.52 M) | |||
| Cash And Equivalents | 762.73 M | |||
| Cash Per Share | 19.06 X | |||
| Total Debt | 783.93 M | |||
| Debt To Equity | 1.60 % | |||
| Book Value Per Share | 11.55 X | |||
| Cash Flow From Operations | (504.36 M) | |||
| Earnings Per Share | (13.10) X | |||
| Total Asset | 1.69 B | |||
About Hansa Biopharma Performance
Assessing Hansa Biopharma's fundamental ratios provides investors with valuable insights into Hansa Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Hansa Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people.Things to note about Hansa Biopharma AB performance evaluation
Checking the ongoing alerts about Hansa Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hansa Biopharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hansa Biopharma AB generated a negative expected return over the last 90 days | |
| Hansa Biopharma AB has high historical volatility and very poor performance | |
| Hansa Biopharma AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 154.53 M. Net Loss for the year was (609.57 M) with profit before overhead, payroll, taxes, and interest of 116.05 M. | |
| Hansa Biopharma AB has accumulated about 762.73 M in cash with (504.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.06. |
- Analyzing Hansa Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hansa Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Hansa Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hansa Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hansa Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hansa Biopharma's stock. These opinions can provide insight into Hansa Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.